PRINCETON, N.J., July 8, 2019 /PRNewswire/ -- Soligenix, Inc.
(Nasdaq: SNGX) (Soligenix or the Company), a late-stage
biopharmaceutical company focused on developing and commercializing
products to treat rare diseases where there is an unmet medical
need, announced today the appointment of Ms. Diane L. Parks to its Board of
Directors.
"We are pleased to welcome Ms. Parks to the Soligenix Board,"
stated Christopher J. Schaber, PhD,
President and CEO of Soligenix. "As Soligenix looks forward to
potential product approval, we intend to leverage Ms. Park's
extensive business and commercialization experience in launching
novel drug therapies in orphan diseases and areas of high unmet
medical need. We believe her expertise will add significantly
to our already diverse and experienced Board of Directors and
management team. We welcome her counsel and look forward to
her contributions to our future success, especially as we look to
complete our pivotal Phase 3 clinical trials of SGX301 for the
treatment of cutaneous T-cell lymphoma and SGX942 for the treatment
of oral mucositis in head and neck cancer patients."
"I am truly excited to be joining the Soligenix Board of
Directors at such an important time in the Company's life cycle,"
stated Ms. Parks. "Having spent the majority of my career
successfully building commercial teams and launching a number of
unique drugs in the biotech and pharmaceutical industry, I am quite
excited to contribute to Soligenix as they begin to position
themselves for potential success with their rare disease
pipeline. I believe Soligenix has the potential for
significant value creation with commercialization of its rare
disease pipeline. I look forward to working closely with the
Board and management team to maximize that
potential."
Ms. Parks is an accomplished businesswoman and commercial
executive with an extensive record of driving profitable growth for
large pharmaceutical and biotech companies. With a successful
career spanning more than 30 years, she served most recently as
Senior Vice President and Head of US Commercial for Kite Pharma,
Inc. (acquired by Gilead Sciences, Inc. for $11.9B), where she was responsible for the launch
of Yescarta®, the first CAR T therapy for large B-cell
lymphoma. Prior to that, she served as Vice President and
Head of Global Marketing for Pharmacyclics, Inc. (acquired by
Abbvie, Inc. for $21B), where she was
responsible for the marketing strategy and launch of
Imbruvica® in Waldenstrom's macroglobulinemia,
chronic lymphocytic leukemia and mantle cell lymphoma. Ms. Parks
also previously served as Vice President of Sales for Amgen Inc.
where she was responsible for the hospital sales team and
subsequently for the Nephrology team supporting Epogen®
and Sensipar®, and as Senior Vice President, Specialty
Biotherapeutics for Genentech, Inc. (acquired by Roche Holdings AG
for $46.8B), where she led the
launches and sales forces for such products as
Nutropin® AQ Pen, Xolair® and
Raptiva®. She is currently on the Boards of
Calliditas Therapeutics AB and Healogix LLC. Ms. Parks holds
a Bachelor of Science degree from Kansas State
University and a Master's degree in Business Administration
from Georgia State University.
About Soligenix, Inc.
Soligenix is a late-stage biopharmaceutical company focused on
developing and commercializing products to treat rare diseases
where there is an unmet medical need. Our Specialized
BioTherapeutics business segment is developing SGX301 as a novel
photodynamic therapy utilizing safe visible light for the treatment
of cutaneous T-cell lymphoma, our first-in-class innate defense
regulator (IDR) technology, dusquetide (SGX942) for the treatment
of oral mucositis in head and neck cancer, and proprietary
formulations of oral beclomethasone 17,21-dipropionate (BDP) for
the prevention/treatment of gastrointestinal (GI) disorders
characterized by severe inflammation including pediatric Crohn's
disease (SGX203) and acute radiation enteritis (SGX201).
Our Public Health Solutions business segment includes active
development programs for RiVax®, our ricin toxin vaccine
candidate and SGX943, our therapeutic candidate for antibiotic
resistant and emerging infectious disease. The development of our
vaccine programs incorporates the use of our proprietary heat
stabilization platform technology, known as
ThermoVax®. To date, this business segment has
been supported with government grant and contract funding from the
National Institute of Allergy and Infectious Diseases (NIAID) and
the Biomedical Advanced Research and Development Authority
(BARDA).
For further information regarding Soligenix, Inc., please visit
the Company's website at www.soligenix.com.
This press release may contain forward-looking statements that
reflect Soligenix, Inc.'s current expectations about its future
results, performance, prospects and opportunities, including but
not limited to, potential market sizes, patient populations and
clinical trial enrollment. Statements that are not historical
facts, such as "anticipates," "estimates," "believes," "hopes,"
"intends," "plans," "expects," "goal," "may," "suggest," "will,"
"potential," or similar expressions, are forward-looking
statements. These statements are subject to a number of
risks, uncertainties and other factors that could cause actual
events or results in future periods to differ materially from what
is expressed in, or implied by, these statements. Soligenix
cannot assure you that it will be able to successfully develop,
achieve regulatory approval for or commercialize products based on
its technologies, particularly in light of the significant
uncertainty inherent in developing therapeutics and vaccines
against bioterror threats, conducting preclinical and clinical
trials of therapeutics and vaccines, obtaining regulatory approvals
and manufacturing therapeutics and vaccines, that product
development and commercialization efforts will not be reduced or
discontinued due to difficulties or delays in clinical trials or
due to lack of progress or positive results from research and
development efforts, that it will be able to successfully obtain
any further funding to support product development and
commercialization efforts, including grants and awards, maintain
its existing grants which are subject to performance requirements,
enter into any biodefense procurement contracts with the U.S.
Government or other countries, that it will be able to compete with
larger and better financed competitors in the biotechnology
industry, that changes in health care practice, third party
reimbursement limitations and Federal and/or state health care
reform initiatives will not negatively affect its business, or that
the U.S. Congress may not pass any legislation that would provide
additional funding for the Project BioShield program. In addition,
there can be no assurance as to timing or success of the Phase 3
clinical trial of SGX942 (dusquetide) as a treatment for oral
mucositis in patients with head and neck cancer receiving
chemoradiation therapy or the Phase 3 clinical trial of SGX301
(synthetic hypericin) for the treatment of cutaneous T-cell
lymphoma. There also can be no assurance as to timing or
success of the preclinical/clinical trials
of RiVaxÒ, that RiVaxÒ will be
approved for the PRV program or the amount for which a PRV
for RiVaxÒ can be sold. These and other risk
factors are described from time to time in filings with the
Securities and Exchange Commission, including, but not limited to,
Soligenix's reports on Forms 10-Q and 10-K. Unless required
by law, Soligenix assumes no obligation to update or revise any
forward-looking statements as a result of new information or future
events.
View original
content:http://www.prnewswire.com/news-releases/soligenix-announces-appointment-of-diane-l-parks-to-its-board-of-directors-300879922.html
SOURCE Soligenix, Inc.